Investment Thesis — Royalty Pharma plc
The market underestimates the durability and growth of Royalty Pharma's royalty streams, anchoring to legacy pharma cyclicality and ignoring the compounding effect of new drug launches. Investors are mispricing the embedded optionality in RPRX's pipeline, treating it as a static cash cow rather than a dynamic platform for innovation exposure.
Catalysts
- Announcement of new royalty acquisitions in high-profile drugs
- Positive clinical readouts from partnered pipeline assets
- Regulatory clarity on royalty structures favoring RPRX's model
Risk Factors
- Major pipeline asset failure or delay
- Adverse regulatory changes to royalty frameworks
- Increased competition for royalty deals compressing returns
Key Debates
RPRX's 36.8% revenue growth sustains, re-rating P/E to 15x by H1 2025.
New royalty deals sustain growth, lifting Fwd P/E above 12x by Q3 2024.
Existing royalty assets maintain 30%+ growth, exceeding $49.40 PT by Q4 2024.